{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T04:14:25Z","timestamp":1742271265797,"version":"3.40.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004961","name":"Minnesota Office of Higher Education","doi-asserted-by":"publisher","award":["MN OHE#15"],"award-info":[{"award-number":["MN OHE#15"]}],"id":[{"id":"10.13039\/100004961","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00415-025-12968-7","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T14:31:31Z","timestamp":1740493891000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Upper motor neuron-predominant motor neuron disease: a novel immunotherapy-responsive association of GAD65 autoimmunity"],"prefix":"10.1007","volume":"272","author":[{"given":"Naveen Kumar","family":"Paramasivan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pallab","family":"Sarker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasia","family":"Zekeridou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan P.","family":"Staff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"McKeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean J.","family":"Pittock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6865-9045","authenticated-orcid":false,"given":"Divyanshu","family":"Dubey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"key":"12968_CR1","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/B978-0-12-802973-2.00013-6","volume":"138","author":"EO Talbott","year":"2016","unstructured":"Talbott EO, Malek AM, Lacomis D (2016) The epidemiology of amyotrophic lateral sclerosis. Handb Clin Neurol 138:225\u2013238","journal-title":"Handb Clin Neurol"},{"key":"12968_CR2","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/S0140-6736(22)01272-7","volume":"400","author":"EL Feldman","year":"2022","unstructured":"Feldman EL, Goutman SA, Petri S, Mazzini L, Savelieff MG, Shaw PJ, Sobue G (2022) Amyotrophic lateral sclerosis. Lancet 400:1363\u20131380","journal-title":"Lancet"},{"key":"12968_CR3","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000385","volume":"4","author":"JA Honorat","year":"2017","unstructured":"Honorat JA, Komorowski L, Josephs KA, Fechner K, St Louis EK, Hinson SR, Lederer S, Kumar N, Gadoth A, Lennon VA, Pittock SJ, McKeon A (2017) IgLON5 antibody: Neurological accompaniments and outcomes in 20 patients. Neurol Neuroimmunol Neuroinflamm 4:e385","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"12968_CR4","doi-asserted-by":"publisher","first-page":"4620","DOI":"10.1007\/s00415-024-12425-x","volume":"271","author":"H Kherbek","year":"2024","unstructured":"Kherbek H, Itoh CY, Daley C, Eggers SD, Hinson S, Sarker P, Staff NP, Pittock SJ, Dubey D (2024) Clinical and serological insights into paraneoplastic brachial amyotrophic diplegia. J Neurol 271:4620\u20134627","journal-title":"J Neurol"},{"key":"12968_CR5","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1007\/s00415-018-8881-0","volume":"265","author":"N Mele","year":"2018","unstructured":"Mele N, Berzero G, Maisonobe T, Salachas F, Nicolas G, Weiss N, Beaudonnet G, Ducray F, Psimaras D, Lenglet T (2018) Motor neuron disease of paraneoplastic origin: a rare but treatable condition. J Neurol 265:1590\u20131599","journal-title":"J Neurol"},{"key":"12968_CR6","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000962","author":"J Werner","year":"2021","unstructured":"Werner J, Jelcic I, Schwarz EI, Probst-Muller E, Nilsson J, Schwizer B, Bloch KE, Lutterotti A, Jung HH, Schreiner B (2021) Anti-IgLON5 disease: a new bulbar-onset motor neuron mimic syndrome. Neurol Neuroimmunol Neuroinflamm. https:\/\/doi.org\/10.1212\/NXI.0000000000000962","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"12968_CR7","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1136\/jnnp-2020-325275","volume":"92","author":"A Budhram","year":"2021","unstructured":"Budhram A, Sechi E, Flanagan EP, Dubey D, Zekeridou A, Shah SS, Gadoth A, Naddaf E, McKeon A, Pittock SJ, Zalewski NL (2021) Clinical spectrum of high-titre GAD65 antibodies. J Neurol Neurosurg Psychiatry 92:645\u2013654","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12968_CR8","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000696","author":"A Munoz-Lopetegi","year":"2020","unstructured":"Munoz-Lopetegi A, de Bruijn M, Boukhrissi S, Bastiaansen AEM, Nagtzaam MMP, Hulsenboom ESP, Boon AJW, Neuteboom RF, de Vries JM, SillevisSmitt PAE, Schreurs MWJ, Titulaer MJ (2020) Neurologic syndromes related to anti-GAD65: clinical and serologic response to treatment. Neurol Neuroimmunol Neuroinflamm. https:\/\/doi.org\/10.1212\/NXI.0000000000000696","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"12968_CR9","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.clineuro.2009.06.005","volume":"111","author":"T Holmoy","year":"2009","unstructured":"Holmoy T, Skorstad G, Roste LS, Scheie D, Alvik K (2009) Stiff person syndrome associated with lower motor neuron disease and infiltration of cytotoxic T cells in the spinal cord. Clin Neurol Neurosurg 111:708\u2013712","journal-title":"Clin Neurol Neurosurg"},{"key":"12968_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci12081053","author":"Z Yang","year":"2022","unstructured":"Yang Z, He L, Ren M, Lu Y, Meng H, Yin D, Chen S, Zhou Q (2022) Paraneoplastic amyotrophic lateral sclerosis: case series and literature review. Brain Sci. https:\/\/doi.org\/10.3390\/brainsci12081053","journal-title":"Brain Sci"},{"key":"12968_CR11","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/146608200300079536","volume":"1","author":"Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron D","year":"2000","unstructured":"Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron D (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1:293\u2013299","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"key":"12968_CR12","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.4065\/73.12.1161","volume":"73","author":"JE Walikonis","year":"1998","unstructured":"Walikonis JE, Lennon VA (1998) Radioimmunoassay for glutamic acid decarboxylase (GAD65) autoantibodies as a diagnostic aid for stiff-man syndrome and a correlate of susceptibility to type 1 diabetes mellitus. Mayo Clin Proc 73:1161\u20131166","journal-title":"Mayo Clin Proc"},{"key":"12968_CR13","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1002\/acn3.51791","volume":"10","author":"NH Chia","year":"2023","unstructured":"Chia NH, McKeon A, Dalakas MC, Flanagan EP, Bower JH, Klassen BT, Dubey D, Zalewski NL, Duffy D, Pittock SJ, Zekeridou A (2023) Stiff person spectrum disorder diagnosis, misdiagnosis, and suggested diagnostic criteria. Ann Clin Transl Neurol 10:1083\u20131094","journal-title":"Ann Clin Transl Neurol"},{"key":"12968_CR14","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1007\/s001250051235","volume":"42","author":"EP Bosi","year":"1999","unstructured":"Bosi EP, Garancini MP, Poggiali F, Bonifacio E, Gallus G (1999) Low prevalence of islet autoimmunity in adult diabetes and low predictive value of islet autoantibodies in the general adult population of northern Italy. Diabetologia 42:840\u2013844","journal-title":"Diabetologia"},{"key":"12968_CR15","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1056\/NEJMoa01167","volume":"345","author":"MC Dalakas","year":"2001","unstructured":"Dalakas MC, Fujii M, Li M, Lutfi B, Kyhos J, McElroy B (2001) High-dose intravenous immune globulin for stiff-person syndrome. N Engl J Med 345:1870\u20131876","journal-title":"N Engl J Med"},{"key":"12968_CR16","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1001\/archneurol.2011.991","volume":"69","author":"A McKeon","year":"2012","unstructured":"McKeon A, Robinson MT, McEvoy KM, Matsumoto JY, Lennon VA, Ahlskog JE, Pittock SJ (2012) Stiff-man syndrome and variants: clinical course, treatments, and outcomes. Arch Neurol 69:230\u2013238","journal-title":"Arch Neurol"},{"key":"12968_CR17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/mus.25565","volume":"56","author":"A McKeon","year":"2017","unstructured":"McKeon A, Tracy JA (2017) GAD65 neurological autoimmunity. Muscle Nerve 56:15\u201327","journal-title":"Muscle Nerve"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-12968-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-12968-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-12968-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T17:42:28Z","timestamp":1742233348000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-12968-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["12968"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-12968-7","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"type":"print","value":"0340-5354"},{"type":"electronic","value":"1432-1459"}],"subject":[],"published":{"date-parts":[[2025,2,25]]},"assertion":[{"value":"18 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N K Paramasivan, P Sarker and NP Staff report no conflicts interest. A.Zekeridou has patents submitted for Tenascin-R-IgG, PDE10A-IgG, and DACH1-IgG as biomarkers of paraneoplastic neurological autoimmunity. She's received research funding from Roche that was used for neurofilament analysis in this work. She's consulted, without personal compensation, for Alexion Pharmaceuticals. CJ Klein has received personal compensation for his service as a consultant in Takeda, Faze Medicine and Sangamo Therapeutics. A.McKeon. is funded by grants from NIH (RO1NS126227, U01NS120901), and has consulted for Janssen and Roche Pharmaceuticals without personal compensation. Dr. McKeon has patents for Septin-5-IgG and Septin-7-IgG licensed to Euroimmun, a patent for GFAP-IgG issued, a patent for MAP1B-IgG with royalties paid to himself and licensed to Ravo Diagnostika, and patents for CAMKV-IgG, KLCHL11-IgG and PDE10A-IgG pending. S.J. Pittock reports receiving grants, personal fees paid to Mayo Clinic, and nonfinancial support from Alexion Pharmaceuticals, Inc. and MedImmune, Inc.\/Viela Bio; receiving personal fees from Genentech\/Roche, UCB, and Astellas, outside the submitted work; holding patent 8,889,102 (application 12-678350) issued and patent 9,891,219B2 (application 12-573942) issued. D. Dubey has consulted for UCB, Immunovant, Argenx, Arialys and Astellas pharmaceuticals. All compensation for consulting activities is paid directly to Mayo Clinic. He is a named inventor on filed patent that relates to KLHL11 as marker of autoimmunity and germ cell tumor. He has patents pending for LUZP4-IgG, cavin-4-IgG and SKOR2-IgG as markers of neurological autoimmunity. He has received funding from the DOD (CA210208 & PR220430), David J. Tomassoni ALS Research Grant Program and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All patients provided consent for participation in this study. The study was approved by the Mayo Clinic Institutional Review Board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"230"}}